Nuvation Bio is trading at $6.92, up 4.29%, mainly on sector strength, with biotech ETF XBI up 2.75% during regular trading.
- No new company-specific announcement, filing, earnings release, or scheduled event was identified for September 2, 2026.
- Recent supportive catalysts include FDA Fast Track designation for safusidenib announced August 20 and bullish analyst coverage, but neither is new today.
- Broader equities are also higher, supporting risk appetite across growth-oriented biotechnology stocks.